Management Team & Board Directors

Management Team

Nicholas Benedict CEO

Nicholas Benedict, CEO

Nicholas Benedict, Chief Executive Officer

Nicholas joined Lumavita in August 2008, bringing with him over 17 years of industry experience. Previously, Nicholas worked at Basilea Pharmaceutica Ltd where he was responsible for commercial strategy and commercial operations worldwide. In this role he set up affiliate companies across the World’s core markets, prepared three products for launch and co-led a successful Secondary Public Offering.

Before Basilea, Nicholas spent 8 years at Novartis in positions including Chief Operating Officer of Novartis UK and head of a Worldwide Business Franchise in Primary Care that included Novartis’ Global Women’s Health business, the number two competitor in Women’s Health Worldwide.

The early part of Nicholas’ career was spent at F. Hoffmann-La Roche in diverse roles, beginning in finance before moving to sales and then to marketing. A British citizen, Nicholas gained his first degree at King’s College in London and has MBAs from Manchester University and Washington University, USA.

Cees Winnips, CSO

Cees Winnips, CSO

Cees Winnips M.D., Chief Scientific Officer

Cees led Lumavita’s corporate reorganisation in 2008. In 2006 he was Chief Scientific Officer with Shogoo Pharmaceuticals AG, Lumavita’s predecessor company, when it acquired Necura's lead project, pentamycin.

From 2004 to 2005 Cees was an advisor to the WHO’s global malaria programme. This was preceded by his appointment as a medical advisor to Wyeth AG from 2003-2004.

Cees’ wide-reaching career in the pharmaceutical industry started in 1989 with Ciba-Geigy in the Netherlands where he was medical advisor and then product manager. He became Head of Product Management for Ciba in Vienna in 1993. Cees transferred to Ciba’s Basel HQ in 1994, as Director, Business Development. After the formation of Novartis he was International Product Manager, Respiratory Franchise until 1998. From then until 2002 Cees was Vice-President for Skyepharma AG’s pulmonary drug-delivery business unit. Cees became a Founder of Necura Pharmaceuticals AG in 2003.

Educated as medical doctor in Amsterdam, Cees has an Advanced Degree in Marketing.

Markus Brand, DFA

Markus Brand, Finance

Markus Brand, Director Finance and Accounting

Markus became Director, Finance and Accounting for Shogoo Pharmaceuticals AG in April 2007, prior to the company’s reorganisation into Lumavita AG in 2008.

In 1999, he joined DHL Management AG (at that time Danzas Management AG) in Basel as Senior Accountant, responsible for accounting and financial reporting. He gained extensive knowledge and hands-on experience in year-end closing for different companies, financial controlling, transfer pricing, implementing new accounting and reporting software as well as International Financial and Reporting Standards (IFRS).

From 1985 to 1999 Markus worked with PricewaterhouseCoopers (formerly Schweizerische Treuhandgesellschaft) as Assistant Manager in auditing and qualified as "Treuhänder mit eidg. Fachausweis". Performing external audits, internal audits and special projects, Markus gained considerable experience in risk analysis, developing audit strategies, year-end audits, consolidation and accounting. He established concepts for a fixed assets register, rules for accounting and assisted in establishing a new accounting system.

Michael Tintiuc, DBD

Michael Tintiuc, Business Development

Michael Tintiuc, Director Business Development

Michael has brought to Lumavita critical skills developed during his previous employment with both start-up and established biotech and pharmaceutical companies. He has served in positions of increasing responsibility for business development and global licensing. Michael joined Lumavita’s predecessor company, Shogoo Pharmaceuticals AG, in 2006 when he was Senior Manager for Global Licensing.

Previously, at Dragon Pharmaceuticals in Vancouver, Michael worked primarily on the business development and marketing of a biosimilar erythropoietin to countries in Asia, Latin-America, and Europe. At Wex Pharmaceuticals in Vancouver, he was Head of Business Development for Wex's tetrodotoxin-derived analgaesic, Tectin®. He then moved to Teijin Pharma in Tokyo, where he managed the business development and international marketing for the company’s entire product portfolio.

Michael has guided Lumavita through the intricacies of global licensing for FemiFect®, carrying out negotiations with pharmaceutical companies in 116 countries. His depth of knowledge about international licensing, marketing and distribution, as well as his formidable linguistic skills contribute immeasurably to the success of Lumavita's global outreach, especially in developing world markets.

Board Directors

Juerg Eckhardt

Juerg Eckhardt, Chairman

Juerg Eckhardt, Chairman

Dr Juerg Eckhardt is an investment advisor for BB BIOTECH VENTURES. He has invested in a wide range of different life science companies.

Before starting his venture capital career, he was an Associate Partner of McKinsey & Co in Zurich and New Jersey/New York, and a member of the firm's European Healthcare Leadership team. Prior to that, Dr Eckhardt was a resident physician at the University Hospital of Basel, Switzerland.

Dr Eckhardt holds an MD from the University of Basel, Switzerland, and an MBA from INSEAD, France. His past or current board assignments include Anteis SA, Calypso Medical Technologies Inc, NeurogesX Inc, TargeGen Inc, and swiss smile Holding AG.

Gerhard Ries

Gerhard Ries

Gerhard Ries

Dr Gerhard Ries is co-founder of BioMedInvest/BioMedCredit and has a strong background in the pharmaceutical, biotechnology and consulting industries.

Previously, Dr Ries was a Partner at InterPharmaLink, a management consulting company, specialising in product portfolio and supply chain optimisation for large Pharma organisations. He also has several years of experience working as a project manager at McKinsey & Co, focusing on Pharma and Life Science companies.

Dr Ries was business development manager at Novartis responsible for licensing opportunities in the Biotech sector. He holds a MS and PhD in Molecular Biology from the University of Basel and a diploma in Biotechnology from the Fachhochschule Weihenstephan. Dr Ries has several years of research experience in the Pharma/Biotech sector gained at Ciba Geigy, Boehringer Mannheim, Harvard Medical School and the Max Planck Institute for Biochemistry.

Karl Naegler

Karl Naegler

Karl Naegler

Karl Naegler is a Principal in the Life Sciences sector, and joined Atlas Venture in 2002.

Previously, he worked as a Scientific Fellow at the National Centre for Scientific Research, Centre for Neurochemistry, in Strasbourg, France.

He obtained his PhD (summa cum laude) for his work in the area of molecular neurobiology at the Max-Delbrück-Centre for Molecular Medicine, Berlin. Karl holds an MSc in Biology with distinction from the Free University of Berlin. He prepared his thesis at the Institute for Biochemistry and Molecular Biology, Monash University in Melbourne, Australia. During his successful academic career, he contributed to several publications in highly respected scientific journals, such as Science and FASEB.

Karl has been instrumental in the formation and financing of several Atlas Venture portfolio companies. He works closely with Egalet, F-Star, Nitec Pharma, Lumavita and U3 Pharma. He serves on the Boards of Nitec Pharma and Lumavita.

Leonz Meyer

Leonz Meyer

Leonz Meyer

Dr Leonz Meyer was a member of the Board when Lumavita’s predecessor company, Shogoo, was incorporated in 2006. He is a business lawyer practicing specifically in Corporate Law, Mergers and Acquisitions (M&A) as well as Intellectual Property.

Dr Meyer is a member of the board of many other Swiss companies in healthcare, medical devices, real estate and financial service provision. This allows him to share with Lumavita his broad experience of Swiss companies. In 2004 he co-founded Schmid Attorneys at Law, which in 2008 became the Swiss arm of Eversheds, one of the World’s largest international law firms. Dr Meyer received his legal training in Basel and Neuchatel (French part of Switzerland) and has worked as a lawyer in Basel, Zurich, Brussels and London.

For the last ten years Dr Meyer has practiced in Zurich, specifically in Corporate Law, M&A and Intellectual Property issues. He speaks and works in German, English and French.

© 2008 Copyright Lumavita AG All rights reserved.